A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment

Psychopharmacology

Volumn 208, Issue 3, 2010, Pages 487-498

  Lipina, Tatiana ^a   Roder, John ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amphetamine; Bupropion; Latent inhibition; Mice; Rolipram; Schizophrenia

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; AMFEBUTAMONE; AMPHETAMINE; CLOZAPINE; HALOPERIDOL; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONDITIONED REFLEX; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG RESPONSE; EMOTION; LATENT INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

AMPHETAMINE; ANIMALS; BUPROPION; CLOZAPINE; CONDITIONING (PSYCHOLOGY); CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; HALOPERIDOL; INHIBITION (PSYCHOLOGY); MALE; MICE; MICE, INBRED C57BL; NEURAL INHIBITION; PIPERAZINES; ROLIPRAM; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77649236681     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1749-3     Document Type: Article

References (82)

1. MD Anglin C Burke B Perrochet E Stamper S Dawud-Noursi 2000 History of the methamphetamine problem J Psychoactive Drugs 32 137 141 10908000 1:STN:280:DC%2BD3M%2FjvVGgsQ%3D%3D
2. Anonymous 1998 Some dugs that cause psychiatric symptoms Med Lett 40 21 24
3. JA Ascher JO Cole JN Colin JP Feighner RM Ferris HC Fibiger RN Golden P Martin WZ Potter E Richelson, et al. 1995 Bupropion: a review of its mechanism of antidepressant activity J Clin Psychiatry 56 395 401 7665537 1:STN:280:DyaK2MzpsVyksw%3D%3D
4. I Baruch DR Hemsley JA Gray 1988 Differential performance of acute and chronic schizophrenics in a latent inhibition task J Nerv Ment Dis 176 598 606 10.1097/00005053-198810000-00004 2903219 1:STN:280:DyaL1M%2Fjs1ajsQ%3D%3D (Pubitemid 18250872)
5. G Biala M Kruk 2009 Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice J Pharm Pharmacol 61 493 502 10.1211/jpp/61.04.0012 19298697 1:CAS:528: DC%2BD1MXntVCgt7Y%3D
6. MD Black GB Varty M Arad S Barak A De Levie D Boulay P Pichat G Griebel I Weiner 2009 Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat Psychopharmacology (Berl) 202 385 396 10.1007/s00213-008-1289-2 1:CAS:528:DC%2BD1MXht1ehu7Y%3D
7. P Bredeloux I Dubuc J Costentin 2007 Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission Br J Pharmacol 150 711 719 10.1038/sj.bjp.0707151 17293887 1:CAS:528: DC%2BD2sXjtFCqtLo%3D (Pubitemid 46440220)
8. D Brustolim R Ribeiro-dos-Santos RE Kast EL Altschuler MB Soares 2006 A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice Int Immunopharmacol 6 903 907 10.1016/j.intimp.2005.12.007 16644475 1:CAS:528:DC%2BD28XjvV2qt7g%3D
9. T Chang U Meyer J Feldon BK Yee 2007 Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice Psychopharmacology (Berl) 191 211 221 10.1007/s00213-006-0649-z 1:CAS:528:DC%2BD2sXitlCksL4%3D (Pubitemid 46354609)
10. SJ Clapcote TV Lipina KJ Millar S Mackie S Christie F Ogawa, et al. 2007 Behavioral phenotypes of Disc1 missense mutations in mice Neuron 54 387 402 10.1016/j.neuron.2007.04.015 17481393 1:CAS:528:DC%2BD2sXmtVOjsrc%3D (Pubitemid 46671409)
11. BR Cooper TJ Hester RA Maxwell 1980 Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo Pharmacol Exp Ther 215 127 134 1:CAS:528: DyaL3cXlvFOktrk%3D
12. SF Crowe J Neath MW Hale 2009 The type 4 phosphodiesterase inhibitors rolipram and YM976 facilitate recall of the weak version of the passive avoidance task in the day-old chick Pharmacol Biochem Behav 92 224 230 10.1016/j.pbb.2008.11.014 19100761 1:CAS:528:DC%2BD1MXitFSntrw%3D
13. JF Cryan C Mombereau A Vassout 2005 The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice Neurosci Biobehav Rev 29 571 625 10.1016/j.neubiorev.2005.03.009 15890404 1:CAS:528:DC%2BD2MXltFWlurk%3D (Pubitemid 40755457)
14. DJ David CE Renard P Jolliet M Hascoët M Bourin 2003 Antidepressant-like effects in various mice strains in the forced swimming test Psychopharmacology (Berl) 166 373 382 1:CAS:528:DC%2BD3sXit12msb8%3D (Pubitemid 36503032)
15. LA Dunn GE Atwater CD Kilts 1993 Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action Psychopharmacology (Berl) 112 315 323 10.1007/BF02244927 1:CAS:528:DyaK2cXks1Y%3D
16. D Duterte-Boucher JM Kamenka J Costentin 1990 Comparison of the effects of three indirect dopamine agonists, GK13, GBR12783 and dexamphetamine on behavioural tests involving central catecholaminergic transmissions Psychopharmacology 101 344 353 10.1007/BF02244052 1972995 1:CAS:528: DyaK3cXkslWitLY%3D (Pubitemid 20193372)
17. AM Elkashef RA Rawson AL Anderson SH Li T Holmes EV Smith, et al. 2008 Bupropion for the treatment of methamphetamine dependence Neuropsychopharmacology 33 1162 1170 10.1038/sj.npp.1301481 17581531 1:CAS:528:DC%2BD1cXjtFOhtb4%3D
18. M El Mansari R Ghanbari S Janssen P Blier 2008 Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain Neuropharmacology 55 1191 1198 10.1016/j.neuropharm.2008.07.028 18708076 1:CAS:528:DC%2BD1cXhtlShurvN
19. LF Fabre DM McLendon 1978 Double-blind placebo controlled study of Wellbutrin in the treatment of depressed in-patients Curr Ther Res Opinion 23 393 402
20. M Fava AJ Rush ME Thase A Clayton SM Stahl JF Pradko, et al. 2005 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL Prim Care Companion J Clin Psychiatry 7 106 113 10.4088/PCC.v07n0305 16027765
21. JF Fischer AK Cho 1979 Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model J Pharmacol Exp Ther 208 203 209 762652 1:CAS:528:DyaE1MXhsV2isbo%3D
22. NS Gray DR Hemsley JA Gray 1992 Abolition of latent inhibition in acute, but not chronic, schizophrenics Neurol Psychiat Brain Res 1 83 89
23. TB Halene SJ Siegel 2008 Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2- imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle J Pharmacol Exp Ther 326 230 239 10.1124/jpet.108.138586 18420599 1:CAS:528:DC%2BD1cXotlyltro%3D (Pubitemid 351872113)
24. WT Howard JK Warnock 1999 Bupropion-induced psychosis Am J Psychiatry 156 2017 2018 10588428 1:STN:280:DC%2BD3c%2FltlKnuw%3D%3D
25. RY Ilyutchenok LV Loskutova AL Finkelberg NI Dubrovina 1992 Neurochemical mechanisms of memory control Acta Physiol Hung 79 419 432 1364180 1:CAS:528:DyaK2cXhsFClsb8%3D
26. JA Johnston CG Lineberry CS Frieden 1986 Prevalence of psychosis, delusions, and hallucinations in clinical trials with bupropion Am J Psychiatry 143 1192 1193 3092682 1:STN:280:DyaL28zitVKqsQ%3D%3D
27. MH Joseph SL Peters JA Gray 1993 Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure Psychopharmacology (Berl) 110 187 192 10.1007/BF02246971 1:CAS:528: DyaK3sXhsVWlu74%3D
28. M Kaneko K Sato R Horikoshi M Yaginuma N Yaginuma M Shiragata, et al. 1992 Effect of haloperidol on cyclic AMP and inositol trisphosphate in rat striatum in vivo Prostaglandins Leukot Essent Fatty Acids 46 53 57 10.1016/0952-3278(92)90059-R 1378633 1:CAS:528:DyaK38Xkt1Sns78%3D
29. SJ Kanes J Tokarczyk SJ Siegel W Bilker T Abel MP Kelly 2007 Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity Neuroscience 144 239 246 10.1016/j.neuroscience.2006.09.026 17081698 1:CAS:528:DC%2BD28Xht12qsLvK (Pubitemid 44839057)
30. S Kim R Westphalen B Callahan G Hatzidimitriou J Yuan GA Ricaurte 2000 Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity J Pharmacol Exp Ther 293 625 633 10773037 1:CAS:528:DC%2BD3cXkvFWgt7k%3D
31. SK Kulkarni K Singh M Bishnoi 2008 Comparative behavioural profile of newer antianxiety drugs on different mazes Indian J Exp Biol 46 633 638 18949892 1:CAS:528:DC%2BD1cXht1Omt7rM
32. SM Learned-Coughlin M Bergström I Savitcheva J Ascher VD Schmith B Langstrom 2003 In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography Biol Psychiatry 54 800 805 10.1016/S0006-3223(02)01834-6 14550679 1:CAS:528:DC%2BD3sXnvFWisLY%3D (Pubitemid 37205131)
33. T Lipina V Labrie I Weiner J Roder 2005 Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia Psychopharmacology 179 54 67 10.1007/s00213-005-2210-x 15759151 1:CAS:528:DC%2BD2MXjtV2iurw%3D (Pubitemid 40576692)
34. Lubow RE (1989) Latent inhibition and conditioned attentional theory. Cambridge University Press, Cambridge
35. GJ Marek G Vosmer LS Seiden 1990 Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons Brain Res 513 274 279 10.1016/0006-8993(90)90467-P 2140952 1:CAS:528: DyaK3cXktlClsr8%3D (Pubitemid 20132265)
36. A Margolin TR Kosten SK Avants J Wilkins W Ling M Beckson, et al. 1995 A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients Drug Alcohol Depend 40 125 131 10.1016/0376-8716(95)01198-6 8745134 1:CAS:528:DyaK28Xht1ajtbY%3D (Pubitemid 26011975)
37. LF Martin WR Kem R Freedman 2004 Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia Psychopharmacology 174 54 64 10.1007/s00213-003-1750-1 15205879 1:CAS:528:DC%2BD2cXmvVahtLc%3D
38. CR Maxwell SJ Kanes T Abel SJ Siegel 2004 Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications Neuroscience 129 101 107 10.1016/j.neuroscience.2004.07.038 15489033 1:CAS:528: DC%2BD2cXos1ykur4%3D (Pubitemid 39360946)
39. U Meyer DL Chang J Feldon BK Yee 2004 Expression of the CS- and US-pre-exposure effects in the conditioned taste aversion paradigm and their abolition following systemic amphetamine treatment in C57BL6/J mice Neuropsychopharmacology 29 2140 2148 10.1038/sj.npp.1300522 15238994 1:CAS:528:DC%2BD2cXhtVSmsrbE (Pubitemid 39578904)
40. MJ Millan R Schreiber A Dekeyne JM Rivet K Bervoets M Mavridis, et al. 1998 S 16924 ((R)-2-[1-[2-(2, 3-dihydro-benzo[1, 4] dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol J Pharmacol Exp Ther 286 1356 1373 9732399 1:CAS:528:DyaK1cXmt1Gqs7Y%3D
41. PC Moser JM Hitchcock S Lister PM Moran 2000 The pharmacology of latent inhibition as an animal model of schizophrenia Brain Res Rev 33 275 307 10.1016/S0165-0173(00)00026-6 11011070 1:CAS:528:DC%2BD3cXmslyjtrs%3D (Pubitemid 30697040)
42. M Neumann V Livak HW Paul G Laux 2002 Acute psychosis after administration of bupropion hydrochloride (Zyban) Pharmacopsychiatry 35 247 248 10.1055/s-2002-36393 12518275 1:STN:280:DC%2BD3s%2Fis1Knug%3D%3D (Pubitemid 36061317)
43. GG Nomikos G Damsma D Wenkstern HC Fibiger 1990 In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis Synapse 6 106 112 10.1002/syn.890060113 1697988 1:CAS:528:DyaK3cXlvVCmurk%3D (Pubitemid 20270704)
44. GG Nomikos G Damsma D Wenkstern HC Fibiger 1992 Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum Neuropsychopharmacology 7 7 14 1381923 1:CAS:528:DyaK38XlvVCks70%3D
45. TJ Phillips HM Kamens JM Wheeler 2008 Behavioral genetic contributions to the study of addiction-related amphetamine effects Neurosci Biobehav Rev 32 707 759 10.1016/j.neubiorev.2007.10.008 18207241 1:CAS:528:DC%2BD1cXjtVegt7o%3D
46. RD Porsolt R Chermat A Lenègre I Avril S Janvier L Stéru 1987 Use of the automated tail suspension test for the primary screening of psychotropic agents Arch Int Pharmacodyn Ther 288 11 30 2889430 1:CAS:528:DyaL2sXlsVKksrk%3D (Pubitemid 17134783)
47. GS Portugal TJ Gould 2007 Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning Pharmacol Biochem Behav 88 179 187 10.1016/j.pbb.2007.08.004 17868796 1:CAS:528:DC%2BD2sXhtFWht7zF (Pubitemid 350116002)
48. B Pouzet MP Andersen S Hogg 2005 Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats Psychopharmacology (Berl) 178 9 16 10.1007/s00213-004-1976-6 1:CAS:528:DC%2BD2MXhtFCqsbY%3D (Pubitemid 40298686)
49. M Raiteri F Cerrito AM Cervoni G Levi 1979 Dopamine can be released by two mechanisms differently affected by the dopamine transporter inhibitor nomifensine J Pharmacol Exp Ther 208 195 202 216794 1:CAS:528:DyaE1MXhsVOisLY%3D
50. RJ Ralph MP Paulus MA Geyer 2001 Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice J Pharmacol Exp Ther 298 148 155 11408536 1:CAS:528:DC%2BD3MXksFChtLc%3D
51. AS Rauhut M Hawrylak SK Mardekian 2008 Bupropion differentially alters the aversive, locomotor and rewarding properties of nicotine in CD-1 mice Pharmacol Biochem Behav 90 598 607 10.1016/j.pbb.2008.05.002 18556053 1:CAS:528:DC%2BD1cXhtVClurnO
52. R Redolat J Vidal MC Gómez MC Carrasco 2005 Effects of acute bupropion administration on locomotor activity in adolescent and adult mice Behav Pharmacol 16 59 62 10.1097/00008877-200502000-00007 15706139 1:CAS:528:DC%2BD2MXht1ygu7c%3D (Pubitemid 40354367)
53. CM Reichel JD Linkugel RA Bevins 2008 Bupropion differentially impacts acquisition of methamphetamine self-administration and sucrose-maintained behavior Pharmacol Biochem Behav 89 463 472 10.1016/j.pbb.2008.02.002 18329085 1:CAS:528:DC%2BD1cXjs1Wnsb0%3D
54. RL Richmond NA Zwar 2003 Review of bupropion for smoking cessation Drug Alcohol Rev 22 203 220 10.1080/09595230100100642 12850907 (Pubitemid 36814872)
55. N Ripoll DJ David E Dailly M Hascoët M Bourin 2003 Antidepressant-like effects in various mice strains in the tail suspension test Behav Brain Res 143 193 200 10.1016/S0166-4328(03)00034-2 12900045 1:CAS:528:DC%2BD3sXlvFyisrg%3D (Pubitemid 36937164)
56. CA Ross RL Margolis SA Reading M Pletnikov JT Coyle 2006 Neurobiology of schizophrenia Neuron 52 139 153 10.1016/j.neuron.2006.09.015 17015232 1:CAS:528:DC%2BD28XhtFentr7I (Pubitemid 44466356)
57. H Russig A Kovacevic CA Murphy J Feldon 2003 Haloperidol and clozapine antagonise amphetamine-induced disruption of latent inhibition of conditioned taste aversion Psychopharmacology (Berl) 170 263 270 10.1007/s00213-003-1544-5 1:CAS:528:DC%2BD3sXovVOhs7c%3D (Pubitemid 37491605)
58. K Rutten C Lieben L Smits A Blokland 2007 The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat Psychopharmacology (Berl) 192 275 282 10.1007/s00213-006-0697-4 1:CAS:528:DC%2BD2sXkslWgtrw%3D (Pubitemid 46669202)
59. R Scott R Bourtchuladze S Gossweiler J Dubnau T Tully 2002 CREB and the discovery of cognitive enhancers J Mol Neurosci 19 171 177 10.1007/s12031-002- 0029-z 12212777 1:CAS:528:DC%2BD38XmvFCqu7s%3D
60. J Scuvée-Moreau I Giesbers A Dresse 1987 Effect of rolipram, a phosphodiesterase inhibitor and potential antidepressant, on the firing rate of central monoaminergic neurons in the rat Arch Int Pharmacodyn Ther 288 43 49 3662698
61. E Shadach I Gaisler D Schiller I Weiner 2000 The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin Neuropsychopharmacology 23 151 161 10.1016/S0893-133X(00)00096-8 10882841 1:CAS:528:DC%2BD3cXksFGjtLs%3D (Pubitemid 30406899)
62. SJ Siegel CR Maxwell S Majumdar DF Trief C Lerman RE Gur, et al. 2005 Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials Neuroscience 133 729 738 10.1016/j.neuroscience.2005.03.027 15908134 1:CAS:528:DC%2BD2MXltFWis70%3D (Pubitemid 40798325)
63. JR Slemmer BR Martin MI Damaj 2000 Bupropion is a nicotinic antagonist J Pharmacol Exp Ther 295 321 327 10991997 1:CAS:528:DC%2BD3cXnt1ynsrg%3D
64. M Stathis U Scheffel SZ Lever JW Boja FI Carroll MJ Kuhar 1995 Rate of binding of various inhibitors at the dopamine transporter in vivo Psychopharmacology (Berl) 119 376 384 10.1007/BF02245852 1:CAS:528: DyaK2MXntFGntrg%3D
65. V Stepanov J Järv 2008 Kinetic mechanism of dopamine transporter interaction with 1-(2-(bis-(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl) piperazine (GBR 12909) Neurochem Int 53 370 373 10.1016/j.neuint.2008.09.005 18845198 1:CAS:528:DC%2BD1cXhsVWrs7bF
66. L Steru R Chermat B Thierry JA Mico A Lenegre M Steru 1987 The automated Tail Suspension Test: a computerized device, which differentiates psychotropic drugs Prog Neuropsychopharmacol Biol Psychiatry 11 659 671 10.1016/0278-5846(87) 90002-9 2894041 1:CAS:528:DyaL1cXhtVGrsbg%3D
67. JM Stone PD Morrison LS Pilowsky 2007 Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review J Psychopharmacol 21 440 452 10.1177/0269881106073126 17259207 1:CAS:528:DC%2BD2sXptFGqu7c%3D (Pubitemid 47077295)
68. E Tiligada E Zampeli K Sander H Stark 2009 Histamine H3 and H4 receptors as novel drug targets Expert Opin Investig Drugs 18 1519 1531 10.1517/14728220903188438 19758107 1:CAS:528:DC%2BD1MXhtFCisLnJ
69. MM Torregrossa JE Folk KC Rice SJ Watson JH Woods 2005 Chronic administration of the delta opioid receptor agonist (+)BW373U86 and antidepressants on behavior in the forced swim test and BDNF mRNA expression in rats Psychopharmacology (Berl) 183 31 40 10.1007/s00213-005-0113-5 1:CAS:528:DC%2BD2MXhtFemurjF (Pubitemid 41484180)
70. EC Warburton MH Joseph J Feldon I Weiner JA Gray 1994 Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron Psychopharmacology (Berl) 114 657 664 10.1007/BF02244998 1:CAS:528: DyaK2cXksV2qurg%3D
71. I Weiner 1990 Neural substrates of latent inhibition: the switching model Psychol Bull 108 442 461 10.1037/0033-2909.108.3.442 1980149 1:STN:280:DyaK3M7gt1Wlsw%3D%3D
72. I Weiner 2003 The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment Psychopharmacology (Berl) 169 257 297 10.1007/s00213-002-1313-x 1:CAS:528:DC%2BD3sXnvVCgsbk%3D (Pubitemid 37264944)
73. I Weiner RE Lubow J Feldon 1984 Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats Psychopharmacology (Berl) 83 194 199 10.1007/BF00429734 1:CAS:528: DyaL2cXksVymt70%3D
74. I Weiner RE Lubow J Feldon 1988 Disruption of latent inhibition by acute administration of low doses of amphetamine Pharmacol Biochem Behav 30 871 878 10.1016/0091-3057(88)90113-X 3227035 1:CAS:528:DyaL1cXmtV2it78%3D (Pubitemid 19270645)
75. I Weiner E Shadach R Tarrasch R Kidron J Feldon 1996 The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine Biol Psychiatry 40 834 843 10.1016/0006-3223(95)00573-0 8896769 1:CAS:528:DyaK28XmvFOguro%3D (Pubitemid 26356717)
76. I Weiner D Schiller I Gaisler-Salomon A Green D Joel 2003 A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine Behav Pharmacol 14 215 222 12799523 1:CAS:528:DC%2BD3sXks1yqtrs%3D
77. J Yamada Y Sugimoto S Yamada 2004 Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test Eur J Pharmacol 504 207 211 10.1016/j.ejphar.2004.09.057 15541423 1:CAS:528:DC%2BD2cXpslGlsbk%3D (Pubitemid 39488216)
78. JW Yates JT Meij JR Sullivan NM Richtand L Yu 2007 Bimodal effect of amphetamine on motor behaviors in C57BL/6 mice Neurosci Lett 427 66 70 10.1016/j.neulet.2007.09.011 17920769 1:CAS:528:DC%2BD2sXht1ams7jO (Pubitemid 47599795)
79. NR Zahniser A Sorkin 2004 Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology 47 Suppl 1 80 91 10.1016/j.neuropharm.2004.07.010 15464127 1:CAS:528:DC%2BD2cXotF2htr4%3D (Pubitemid 39298254)
80. MR Zarrindast MR Hodjati A Pejhan E Soleimannejad 1996 Bupropion induces sniffing: a possible dopaminergic mechanism Eur Neuropsychopharmacol 6 299 303 10.1016/S0924-977X(96)00034-X 8985713 1:CAS:528:DyaK28Xnt1KrtLw%3D (Pubitemid 26422790)
81. HT Zhang LR Whisler Y Huang Y Xiang JM O'Donnell 2009 Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior Neuropsychopharmacology 34 1067 1077 10.1038/npp.2008.184 18923403 1:CAS:528:DC%2BD1MXhs1ansbg%3D
82. WWK Zung 1983 Review of placebo controlled trials with bupropion J Clin Psychiatry 44 104 114 6406436 1:STN:280:DyaL3s3htlWquw%3D%3D